Their findings showed: Osteoporosis: About 4% of GLP-1 users developed osteoporosis, compared with just over 3% of non-users Osteomalacia (softening of the bones): Occurred nearly twice as often among GLP-1 users Gout: Occurred in 7.4% of GLP-1 users vs
GLP-1 Receptor Agonist Market Competitive Landscape Major Competitors are: Other Competitors Include: GLP-1 Receptor Agonist Market Trends Major trends shaping the GLP-1 receptor agonist market include: Development Of Oral GLP-1 Candidates To Expand Patient Convenience And Treatment Accessibility Major companies in the GLP-1 receptor agonist market are focusing on the development of oral GLP-1 formulations designed to address rising global demand for more convenient, non-injectable metabolic therapies
While Ozempic is not FDA-approved for weight loss or PCOS treatment, it may be prescribed off-label, with ongoing research indicating its potential to improve PCOS symptoms through hormone regulation and metabolism improvement
But doesn't have the issues of Adderall
Ozempic commonly causes nausea, vomiting, and digestive changes in the first 4-8 weeks that typically improve with continued use
Taking a Detailed Medication History One of the first steps doctors take is asking patients what medications they are taking